Laropiprant recalled


Merck & Co has said it is recalling Tredaptive cholesterol tablets in response to trial results that raised safety concerns and the recommendations of a European Medicines Agency safety panel.

Tredaptive tablets are approved in the EU and elsewhere – but not in the US – for treating patients with high cholesterol levels. They contain niacin (vitamin B3), which increases levels of ‘good’ HDL cholesterol, and laropiprant, a patent protected compound designed to reduce facial flushing, a common side effect of taking niacin.

The data suggest that the tablets are not as effective as hoped at reducing heart attacks, deaths and strokes in patients with high levels of ‘bad’, LDL cholesterol. They also suggest that the side effects are worse than expected.

Merck & Co said that doctors should stop prescribing the drug and review treatment plans for patients already taking it.

US regulators rejected laropiprant for market approval in 2008.


Related Content

HDL drug class struggling after latest flop

27 May 2012 Business

news image

The failure of another 'good' cholesterol-raising drug and a new genetic study casts shadow over HDL hypothesis

Business roundup

5 January 2011 Business

news image

Industry news, January2011

Most Commented

Countries ink Paris climate change agreement

27 April 2016 News and Analysis

news image

Nearly 200 countries signed the global climate treaty that aims to limit temperature rises to ‘well below’ 2°C

Shadow of Chernobyl

26 April 2016 Critical Point

news image

Mark Peplow takes the long view on the cost of nuclear power